Korro Bio Inc (KRRO) Stock Price, Quote & News

Company Profile

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The c...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 468 1999

Website: www.korrobio.com

Address:

One Kendall Square, Building 600-700 Suite 6-401, Cambridge, United States

directorwalsh Oct. 24 at 4:16 AM

$KRRO profit taking after a big run is fine I’m a buyer down here. Sticking around with Atlas for $100 or so

0 · Reply

Doozio Oct. 15 at 10:24 PM

$KRRO it was always 🐒🍌🧠⏰♾️ wen “allegedly” became…..

0 · Reply

ChazzyTrades Oct. 15 at 7:34 PM

$KRRO buying here

0 · Reply

History101 Oct. 9 at 4:13 PM

$KRRO 2,419 watching 10/9/2025

0 · Reply

History101 Oct. 8 at 11:27 PM

$CRSP why did CRSP rise over 8% today, and $KRRO dropped 6%? anyone know?

0 · Reply

FadeLars Oct. 5 at 9:30 AM

$KRRO Technology services micro-cap. No clear pattern. Illiquid conditions. Avoid.

0 · Reply

Mehrtuerer Sep. 23 at 3:34 PM

$KRRO Any news?

0 · Reply

History101 Sep. 17 at 8:05 PM

$KRRO added

0 · Reply

stephllllll Sep. 10 at 2:19 PM

$KRRO 40$ by friday night

0 · Reply

Sw1ngb0t Sep. 5 at 9:15 PM

$KRRO $39.12+ next

0 · Reply

Korro to Participate in Upcoming Investor and Scientific Conferences

Aug 12, 2025, 7:00 AM EDT - 2 months ago

Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates

Jul 21, 2025, 8:00 AM EDT - 3 months ago

Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110

May 14, 2025, 4:05 PM EDT - 5 months ago

Korro to Participate in Upcoming Investor Conferences

May 7, 2025, 4:30 PM EDT - 6 months ago

Korro Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 1, 2025, 7:30 AM EDT - 7 months ago

Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer

Mar 18, 2025, 7:00 AM EDT - 7 months ago

Korro Reports Full Year 2024 Financial Results and Provides Business Updates

Mar 14, 2025, 8:00 AM EDT - 8 months ago

KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency

Feb 26, 2025, 8:00 AM EST - 8 months ago

Korro to Present at the TD Cowen 45th Annual Health Care Conference

Nov 21, 2024, 7:30 AM EST - 1 year ago

Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency

Nov 14, 2024, 8:00 AM EST - 1 year ago

Korro to Present at the Jefferies London Healthcare Conference

Nov 4, 2024, 7:25 AM EST - 1 year ago

Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Korro to Participate in Upcoming September Investor and Scientific Conferences

Aug 13, 2024, 4:01 PM EDT - 1 year ago

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

May 30, 2024, 4:01 PM EDT - 1 year ago

Korro to Participate in Upcoming June Investor and Scientific Conferences

May 20, 2024, 2:30 PM EDT - 1 year ago

Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference

May 14, 2024, 4:01 PM EDT - 1 year ago

Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer

Apr 18, 2024, 8:30 AM EDT - 1 year ago

Korro Announces $70 Million Private Placement

Mar 26, 2024, 4:01 PM EDT - 1 year ago

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

Mar 14, 2024, 5:34 PM EDT - 1 year ago

Newer Treatments In Alpha-1 Antitrypsin Deficiency: $2.5 Billion/Year Market Size By 2032

KRYS MREO TAK WVE

Feb 27, 2024, 8:00 AM EST - 1 year ago

Korro to Present at the TD Cowen 44th Annual Health Care Conference

Jan 18, 2024, 8:00 AM EST - 1 year ago

Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio

Jan 4, 2024, 8:00 AM EST - 1 year ago

Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 7, 2023, 8:00 AM EST - 2 years ago

Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

Nov 28, 2023, 8:00 AM EST - 2 years ago

Korro Bio Appoints Dr. Rachel Meyers to Board of Directors

Nov 3, 2023, 3:31 PM EDT - 2 years ago

UPDATE: Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Nov 3, 2023, 12:19 PM EDT - 2 years ago

Korro Bio and Frequency Therapeutics Announce Closing of Merger and Private Placement of $117 Million

Oct 6, 2023, 2:14 PM EDT - 2 years ago

FREQUENCY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Frequency Therapeutics, Inc. - FREQ

Aug 10, 2023, 4:01 PM EDT - 2 years ago

Frequency Therapeutics Provides Business Updates and Second Quarter 2023 Financial Results

Jul 14, 2023, 6:30 AM EDT - 2 years ago

Korro Bio and Frequency Therapeutics Announce Merger Agreement

May 12, 2023, 4:01 PM EDT - 2 years ago

Frequency Therapeutics Provides Business Updates and First Quarter 2023 Financial Results

Mar 10, 2023, 7:30 AM EST - 2 years ago

Frequency Therapeutics Provides Business Updates and Fourth Quarter and Full Year 2022 Financial Results

Feb 27, 2023, 7:30 AM EST - 2 years ago

Frequency Therapeutics to Participate at Upcoming March Investor Conferences

Feb 23, 2023, 7:45 AM EST - 2 years ago

Small Animal Imaging In Vivo Market is Anticipated to Reach a Value of USD 6.1 Billion by Growing at a CAGR of 8.89% During 2022-2028; Expanding Healthcare Sector and Rising Clinical Research to Elevate Market Growth

Feb 13, 2023, 8:05 AM EST - 2 years ago

Frequency Therapeutics Announces Topline Results for its Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Dec 19, 2022, 7:30 AM EST - 3 years ago

Frequency Therapeutics Announces Formation of Clinical Advisory Board for Remyelination in Multiple Sclerosis Program

Dec 15, 2022, 7:30 AM EST - 3 years ago

Frequency Therapeutics Announces First Patient Dosed in Phase 1b Study of FX-345, the Company's Second Therapeutic Candidate for Sensorineural Hearing Loss

Nov 17, 2022, 7:30 AM EST - 3 years ago

Frequency Therapeutics to Host Virtual Investor Event, Highlighting Hearing Restoration Candidate FX-322 in Advance of Q1 Clinical Results

Nov 8, 2022, 4:05 PM EST - 3 years ago

Frequency Therapeutics Provides Business Updates and Third Quarter 2022 Financial Results

Oct 12, 2022, 7:30 AM EDT - 3 years ago

Frequency Therapeutics Completes Enrollment of Phase 2b Study of FX-322 for the Treatment of Sensorineural Hearing Loss

Aug 30, 2022, 7:30 AM EDT - 3 years ago

Frequency Therapeutics to Participate in September Investor and Medical Conferences

Aug 9, 2022, 4:05 PM EDT - 3 years ago

Frequency Therapeutics Provides Business Updates and Second Quarter 2022 Financial Results

May 18, 2022, 7:30 AM EDT - 3 years ago

Frequency Therapeutics to Participate in 2022 H.C. Wainwright Global Investment Conference

May 4, 2022, 4:30 PM EDT - 3 years ago

Frequency Therapeutics Provides Business Updates and First Quarter 2022 Financial Results

Apr 22, 2022, 7:30 AM EDT - 3 years ago

Frequency Therapeutics to Participate in B. Riley Securities' Neuro & Ophthalmology Investor Conference

Mar 15, 2022, 7:30 AM EDT - 3 years ago

Frequency Therapeutics Provides Business Updates and Reports Fourth Quarter and Full Year 2021 Financial Results

directorwalsh Oct. 24 at 4:16 AM

$KRRO profit taking after a big run is fine I’m a buyer down here. Sticking around with Atlas for $100 or so

0 · Reply

Doozio Oct. 15 at 10:24 PM

$KRRO it was always 🐒🍌🧠⏰♾️ wen “allegedly” became…..

0 · Reply

ChazzyTrades Oct. 15 at 7:34 PM

$KRRO buying here

0 · Reply

History101 Oct. 9 at 4:13 PM

$KRRO 2,419 watching 10/9/2025

0 · Reply

History101 Oct. 8 at 11:27 PM

$CRSP why did CRSP rise over 8% today, and $KRRO dropped 6%? anyone know?

0 · Reply

FadeLars Oct. 5 at 9:30 AM

$KRRO Technology services micro-cap. No clear pattern. Illiquid conditions. Avoid.

0 · Reply

Mehrtuerer Sep. 23 at 3:34 PM

$KRRO Any news?

0 · Reply

History101 Sep. 17 at 8:05 PM

$KRRO added

0 · Reply

stephllllll Sep. 10 at 2:19 PM

$KRRO 40$ by friday night

0 · Reply

Sw1ngb0t Sep. 5 at 9:15 PM

$KRRO $39.12+ next

0 · Reply

topstockalerts Sep. 5 at 6:30 PM

$KRRO this setup continues to provide opportunities.. stay tuned!

0 · Reply

Mehrtuerer Sep. 5 at 6:05 PM

$KRRO I am 82% plus with this stock. Normally I sell stocks and loose my money. ;) What's happening? What are the news?

0 · Reply

stephllllll Sep. 5 at 3:22 PM

$KRRO Wow, that thing is swinging today. See you at 100$

1 · Reply

_www_larval_com_ Sep. 5 at 3:07 PM

$KRRO has soared 8% higher to 9% (~146Kv) in the last few minutes, follow for more volatility.

0 · Reply

NVDAMillionaire Sep. 5 at 2:18 PM

$KRRO Brilliant piece that captures KRRO's situation perfectly. So if you want to update your understanding of KRRO or get to know KRRO better, this is essential reading. https://beyondspx.com/quote/KRRO/korro-bio-s-rna-editing-frontier-precision-pipeline-and-path-to-value-nasdaq-krro#analysis

0 · Reply

Moneyprintertothemars Sep. 5 at 1:47 PM

$KRRO Not today. I think it will drop soon

0 · Reply

Bombay55 Sep. 3 at 10:53 PM

$KRRO looking at the price action this could be the next buyout candidate

0 · Reply

Quantumup Sep. 3 at 6:20 PM

Leerink⬆️ $WVE's PT to $26 from $24, reit'd Outperform & said it thinks invs should take advantage of weakness to buy, ahead of add'l important catalysts, which they remain optimistic investors will appreciate. $GSK $ARWR TAK $KRRO SNY NTLA BEAM $LLY NVO VKTX GPCR Raymond James reit'd $WVE Outperform-$14 & said, We continue to view $WVE's wholly-owned gene-editing programs as more likely LT value drivers - sees WVE-007 (INHBE) in obesity (4Q 2025) as the most important near-term stock-moving catalyst, with an attractive risk/ reward skew. Leerink and Raymond James said in their notes to investors:

1 · Reply

Bigeyes2 Sep. 3 at 3:51 PM

$KRRO 🎯

0 · Reply

bd2667 Aug. 30 at 12:21 AM

$BEAM $KRRO Beam - 302 Vs KRRO - 110?

0 · Reply

Market Cap	352.16M
Revenue (ttm)	2.27M
Net Income (ttm)	-83.58M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-3,681.94%
Debt to Equity Ratio	0.00

Volume	251,700
Avg Vol	247,914
Day's Range	N/A - N/A
Shares Out	9.39M
Stochastic %K	8%
Beta	2.89
Analysts	Strong Sell
Price Target	$92.33